Hereditary ATTR (hATTR) amyloidosis is the most common form of ATTR and also a very rare disease. Familial Amyloidosis Polyneuropathy (FAP) and Familial Amyloidosis cardiomyopathy (FAC) are the two common types of hATTR.
The Hereditary Transthyretin Amyloidosis (hATTR) Market size in the 7MM was estimated to be USD 306.9 Million in 2017 and is anticipated to grow further in the forecast period 2020-30 owing to recent approvals and pipeline therapies. Among the 7MM geographies, the United States accounted for the 54% share of the total hATTR market size.
The key pharma companies in the Hereditary transthyretin amyloidosis market includes Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Inc., Eidos Therapeutics, and many others.
For more details on Hereditary Transthyretin Amyloidosis (hATTR) Market, visit: https://www.delveinsight.com/blog/hattr-market-hereditary-transthyretin-amyloidosis-market/